The invention relates to inhibitors of PI5P4K inhibitors useful in the treatment of cancers, neurodegenerative diseases, inflammatory disorders, and metabolic diseases, having the Formula: ##STR00001##
where A1, A2, G, R1, R2, R3, R4, and W are described herein.

The present invention provides compounds of Formula (I):

##STR00001##

or stereoisomers, tautomers, or pharmaceutically-acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.

The present disclosure provides a compound of Formula (I):

##STR00001##

or a pharmaceutically acceptable salt thereof as described herein. The present disclosure also provides pharmaceutical compositions comprising a compound of Formula (I), processes for preparing compounds of Formula (I), and therapeutic methods for treating inflammatory disease.

An organic electroluminescence device includes an anode, a cathode, and one or more organic thin film layers including an emitting layer disposed between the cathode and the anode. Also, the organic thin film layer includes an electron-transporting zone provided between the emitting layer and the cathode. The organic thin film layer contains at least one compound of the polycyclic compound (Ia) or (Ib):

##STR00001##

An organic electroluminescence device includes an anode, a cathode, and one or more organic thin film layers including an emitting layer disposed between the cathode and the anode. Also, the organic thin film layer includes an electron-transporting zone provided between the emitting layer and the cathode. The organic thin film layer contains at least one compound of the polycyclic compound (Ia) or (Ib):

##STR00001##

Disclosed are compounds of Formula (I′), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections. ##STR00001##

Disclosed are compounds of Formula (I′), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections. ##STR00001##

Compounds are provided having the structure of Formula (I) or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, tautomer, isotope, or salt thereof, wherein A, X, R.sup.3, R.sup.5, R.sup.6, R.sup.7, R.sup.8, Y.sup.2, Y.sup.4, Y.sup.6, Y.sup.7, Y.sup.8, Y.sup.9, m, and n are as defined herein. Such compounds inhibit tyrosine kinase receptors, particularly the platelet derived growth factor receptor-alpha (PDGFR-α) and/or the platelet derived growth factor receptor-beta (PDGFR-β). Products containing such compounds, as well as methods for their use and preparation, are also provided.

##STR00001##

In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.

##STR00001##

In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.

##STR00001##